147 related articles for article (PubMed ID: 3802077)
1. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
[TBL] [Abstract][Full Text] [Related]
2. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
3. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
5. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
Evans DL; Tilby M; Dive C
Cancer Res; 1994 Mar; 54(6):1596-603. PubMed ID: 8137265
[TBL] [Abstract][Full Text] [Related]
7. The formation and persistence of carboplatin-DNA adducts in rats.
Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
[TBL] [Abstract][Full Text] [Related]
8. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
9. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
[TBL] [Abstract][Full Text] [Related]
10. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
11. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
[TBL] [Abstract][Full Text] [Related]
12. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.
Terheggen PM; Floot BG; Scherer E; Begg AC; Fichtinger-Schepman AM; den Engelse L
Cancer Res; 1987 Dec; 47(24 Pt 1):6719-25. PubMed ID: 3315190
[TBL] [Abstract][Full Text] [Related]
15. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
